The GHK-Cu studies reviewed here do not establish a standard human subcutaneous dose of 1-4 mg per day, a daily injection schedule, or a four-to-six-week cycle. Those quantities appeared in the previous version of this guide without a supporting human dose-finding study. The useful distinction is between a concentration used in cell research, an animal wound experiment, a topical formulation and an injected amount.
What the actual GHK-Cu studies measured
| Study | Population and route | What it contributes to a dosage question |
|---|---|---|
| Maquart, 1988, PMID 3169264 | Fibroblast cultures exposed to GHK-Cu | Collagen synthesis began increasing around 10^-12 to 10^-11 mol/L and peaked around 10^-9 mol/L. These are culture concentrations, not patient doses in mg/day. |
| Maquart, 1993, PMID 8227353 | Rats with implanted wound chambers; injections into those chambers | Connective-tissue accumulation changed with concentration. An injection into an experimental rat wound chamber is not a human subcutaneous treatment regimen. |
| Miller, 2006, PMID 16847171 | Topical products after CO2 laser resurfacing; 13 patients completed | No significant between-group advantage in objective redness resolution, wrinkles or skin quality; patient satisfaction was higher. This does not identify an injected dose. |
| CuHeal, NCT07437586 | Registered topical gel study, planned enrollment 60 adults | The record describes 0.1% w/w gel applied daily for 14 days. It has no posted results and cannot supply an effective injection dose. |
How to read the registered topical concentration
The CuHeal record last updated February 27, 2026 lists recruiting status and an estimated primary completion date of February 14, 2027. It describes approximately 0.5 g of 0.1% w/w gel per application. Arithmetically, 0.1% of 0.5 g is 0.0005 g, or 0.5 mg, of ingredient in that topical application. This quantity describes gel applied to a wound. It does not establish how much reaches tissue or blood and cannot be converted into a subcutaneous dose. A registered protocol is different from published treatment results.
Vial mass, concentration and delivered amount
A vial labeled 5 mg describes total stated mass. It does not specify a daily dose. Once a final concentration is known, the dimensional calculation is amount in mg = concentration in mg/mL multiplied by volume in mL. For example, a solution with a stated concentration of 2.5 mg/mL contains 0.25 mg in 0.1 mL. This is an arithmetic example, not a recommendation to prepare or inject that solution.
From the FormBlends catalog
GHK-Cu (Copper Peptide)
A copper peptide studied for skin and tissue support · From $179/mo · compounded by a licensed 503A pharmacy, dispensed only after provider review.
View GHK-Cu (Copper Peptide) →The numbers on a syringe describe its volume scale, not a peptide-specific dose. On a U-100 scale, 10 marks represent 0.1 mL. The amount in mg still depends on the actual concentration. A vial's fill weight, a final solution concentration and a prescribed amount are three different inputs.
What supports cycling or maintenance schedules?
The cited cell, rat and topical studies do not test a human subcutaneous schedule of four-to-six weeks on and two-to-four weeks off, twice-daily injections, or three days a week for maintenance. They also do not demonstrate that such cycling prevents receptor desensitization. A schedule described online is not equivalent to a tested regimen with a defined population, route, dose and outcome.
Storage depends on the actual formulation
A universal 28-day shelf life for every reconstituted GHK-Cu vial is not established by these studies. Stability depends on formulation, concentration, container, preparation and the conditions assessed. The pharmacy or manufacturer instructions for the actual product identify its storage and beyond-use period; a general peptide article cannot supply those product-specific measurements.
Safety and side effects
The reviewed research does not provide a reliable frequency of human injection reactions or establish that injected GHK-Cu is generally well tolerated. A peptide occurring naturally in the body does not, by itself, determine the effects of a particular administered formulation.
Don't self-adjust your dose without consulting your provider.
Frequently asked questions
Is 1-4 mg per day an established research dose?
The primary studies cited here do not establish that range as a standard human subcutaneous dose. The original guide did not identify a human trial supporting it.
Does a topical concentration determine an injected dose?
No. A gel's concentration and applied mass describe a different route and exposure. They are not a validated conversion to mg injected.
What should a dose claim cite?
A study of the same compound, formulation, route and population, with the administered dose and outcome reported. Cell concentrations and animal experiments answer different questions.
Sources
- Maquart et al.: GHK-Cu and collagen synthesis in fibroblast cultures
- Maquart et al.: GHK-Cu in rat experimental wound chambers
- Miller et al.: topical copper tripeptide after CO2 laser resurfacing
- CuHeal: registered topical GHK-Cu gel trial, NCT07437586
Disclaimer: This article is for informational purposes only and doesn't constitute medical advice. GHK-Cu isn't FDA-approved for any medical condition. The dosing information presented here is based on the cited research and distinguishes studied quantities from unvalidated protocols and shouldn't be used as a substitute for professional medical guidance. Always consult with a licensed healthcare provider before beginning any peptide therapy. Individual results may vary. FormBlends doesn't claim that GHK-Cu cures, treats, or prevents any disease.
Ready when you are
GHK-Cu (Copper Peptide)
A copper peptide studied for skin and tissue support · From $179/mo · compounded by a licensed 503A pharmacy, dispensed only after provider review.
View GHK-Cu (Copper Peptide) →